Source: Clinical Nuclear Medicine. Unidade: FM
Subjects: DOSIMETRIA, IODO, MEDICINA NUCLEAR (TRATAMENTO), DOENÇA DE GRAVES, GLÂNDULA TIREOIDE, HIPERTIREOIDISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAPIENZA, Marcelo Tatit et al. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial. Clinical Nuclear Medicine, v. 40, n. 9, p. 715-719, 2015Tradução . . Disponível em: https://doi.org/10.1097/RLU.0000000000000840. Acesso em: 01 nov. 2024.APA
Sapienza, M. T., Coura-Filho, G. B., Willegaignon, J., Watanabe, T., Duarte, P. S., & Buchpiguel, C. A. (2015). Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial. Clinical Nuclear Medicine, 40( 9), 715-719. doi:10.1097/RLU.0000000000000840NLM
Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial [Internet]. Clinical Nuclear Medicine. 2015 ; 40( 9): 715-719.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1097/RLU.0000000000000840Vancouver
Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial [Internet]. Clinical Nuclear Medicine. 2015 ; 40( 9): 715-719.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1097/RLU.0000000000000840
